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Abstract: Low doses of granulocyte- colony stimulating factor (G-CSF) and granulocyte macrophage- colony 
stimulating factor (GM-CSF) have been shown to be beneficial in reducing duration of systemic antibiotic therapy and 
in-patient hospitalization by decreasing the period of neutropenia in cancer patients undergoing chemotherapy. Since the 
underlying mechanism is unclear, the aim of this study was to investigate whether the administration of G-CSF and GM-
CSF in two different doses (low dose and standard dose) would result into resolution of neutropenia with concomitant 
increase in multiple forms of dihydrofolate reductase (DHFR, a pivotal enzyme in the pathway of de novo DNA 
synthesis). Thirty seven cancer patients (26 males and 11 females; age 14-73 years) having chemotherapy-induced 
neutropenia (absolute neutrophil counts <500/µl) were treated with colony stimulating factor (CSF) in the following 
manner: 11 received GM-CSF (7 received a dose 250 µg/m2 and 4 received a dose of 100 µg/m2); 26 received G-CSF 
(14 received a dose of 5 µg/kg and 12 received a dose of 2.5 µg/kg). CSFs was given every day till the absolute 
neutrophil count was more than 1,000/µl. Ten ml blood was collected from each patient and analyzed for total leukocyte 
count (TLC) and active DHFR and immunoreactive nonfunctional form of DHFR (IRE) in the cytoplasm of blood 
leukocytes by using methotrexate binding assay and enzyme-linked immunosorbent assay (ELISA). A significant 
increase (p<0.05) in concentrations of both active DHFR and IRE following stimulation with low as well as standard 
doses of CSFs was observed along with increase in the TLC. There was no significant difference in number of days to 
resolution of neutropenia at these two doses, indicating that even low doses of CSFs are clinically effective. Along with 
an increase in TLC, the levels of DHFR increased even at low doses of CSF suggesting that this might be one of the 
mechanisms for CSF-induced proliferation of leukocytes in neutropenic cancer patients. 
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INTRODUCTION 
 
Granulocyte-colony stimulating factor (G-CSF) and 
granulocyte macrophage-colony stimulating factor (GM-
CSF) have been widely used as therapeutic agents for 
early regeneration of white blood cells in neutropenic 
patients following standard or high-dose chemotherapy 
(Vose and Armitage, 1995). A meta-analysis of a number 
of randomized controlled trials to evaluate safety and 
efficacy of colony-stimulating factors (CSFs) in patients 
with febrile neutropenia revealed that these CSFs reduce 
the time spent in hospital and time to recovery of 
neutrophils in these patients (Clark et al., 2005). In 
particular, G-CSF is widely recommended for prophylaxis 
of febrile neutropenia for at-risk patients. The American 
Society of Clinical Oncology (ASCO), the National 
Comprehensive Cancer Network (NCCN), the European 
Society of Medical Oncology (ESMO) and the European 
Organization of Research and Treatment of Cancer 
(EORTC) recommend that G-CSF should be prescribed 
prophylactically for all patients in whom the risk of 
neutropenia is more than 20% (Aapro et al., 2006). 
Guidelines have been published, and algorithms have 
been developed to predict the at-risk patients (Ozer et al., 
2000, Aapro et al., 2006, de Naurois et al., 2010). 
Prophylactic administration of G-CSF decreases the risk 
of febrile neutropenia by 50%. Nevertheless, a significant 
proportion of patients develop febrile neutropenia, and G-
CSF is prescribed together with the antibiotics, and this 
has been shown to reduce the duration of neutropenia. 
However, the prohibiting factor in widespread use of G-
CSF is the cost.  
 
In order to be more cost-effective, even half of the 
conventional doses of CSFs have been used in these 
patients and were found to be comparable in clinical 
efficacy to standard doses (Burney et al., 2003). However, 
the mechanism whereby these CSFs promote granulocytes 
proliferation remains unclear. A few reports from our 
laboratory have shown that increased levels of multiple 
forms of dihydrofolate reductase (DHFR) – an important 
enzyme in the pathway of de novo DNA synthesis might 
be involved (Iqbal et al., 2000A; Iqbal et al., 2000B; Iqbal 
et al., 2001). However, whether the effect of low doses of 
CSFs is also through increased levels of DHFR needs to 
be explored. The present study was carried out to find out 
whether or not the administration of G-CSF and GM-CSF 
at two different doses (low dose and standard dose) would *Corresponding author: e-mail: perwaiz.iqbal@aku.edu
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result into resolution of neutropenia in myelosuppressed 
cancer patients through increased levels of DHFR. 
 
PATIENTS AND METHODS 
 
In this prospective study, 37 cancer patients (26 males and 
11 females; age range 14 to 73 years) admitted to the Aga 
Khan University Hospital were enrolled with informed 
consent. Demographic and clinical characteristics of these 
patients have been listed in table 1. They all had 
chemotherapy-induced febrile neutropenia with absolute 
neutrophil count less than 500/µl and fever greater than 
38.5°C. The study had been approved by the Ethics 
Review Committee of the Aga Khan University. Eleven 
patients received GM-CSF (Molgrastim, Novartis, Basel, 
Switzerland). Seven of them were given a dose of 250 
µg/m2, while 4 received a dose of 100 µg/m2. Similarly, 
14 patients were given G-CSF (Filgrastim, Roche, Basel, 
Switzerland) at a dose of 5 µg/kg body weight, while 12 
were given G-CSF at a dose of 2.5 µg/kg body weight. 
The CSF was given every day till the absolute neutrophil 
count was greater than 1000/µl. Details of clinical 
parameters have been provided in a previous paper 
(Burney et al., 2003). Ten ml blood was collected in a 
heparinized tube from each patient before the 
administration of CSF and upon resolution of neutropenia. 
A portion of blood was analyzed on Coulter Counter for 
full blood cell count. Leukocytes were removed from rest 
of the blood sample and cytoplasmic extract was prepared 
as described in a previous publication (Rothenberg and 
Iqbal, 1982). The cytoplasmic samples were subjected to 
analysis for active DHFR and for total immunoreactive 
DHFR by using methotrexate binding assay and enzyme-
linked immunosorbent assay, respectively (Rothenberg et 
al., 1977; Iqbal and Hussain, 1991, Iqbal et al., 1992). 
The actual concentration of immunoreactive but 
functionally inactive form of DHFR (IRE) was obtained 
after subtracting the active DHFR concentration from 
total immunoreactive DHFR. Cytoplasmic samples were 
analyzed for protein concentration by the Lowry method 
(Lowry et al., 1951). 
 
In vitro effect of CSF on white blood cells 
In order to study the effect of CSF on white blood cells in 
blood culture, 10 ml of venous blood was drawn from 
healthy volunteers with informed consent. Blood was 
stimulated with rhu GM-CSF (specific activity 1.8 x 108 
U/mg; Immunex Corporation, Seattle, Washington, USA) 
in two doses 0.5 units/ml and 80 units/ml in culture tubes. 
The reaction also contained penicillin (1000 units/ml) and 
streptomycin 0.1 mg/ml. The culture tubes were incubated 
at 37°C for 16 hours in 5% CO2 incubator. TLC was 
determined before as well as after incubation. White 
blood cells were removed and lysed from each reaction. 
Cytoplasm was prepared and analyzed for active DHFR 
and IRE as described above. 
 
STATISTICAL ANALYSIS 
 
All statistical analyses were carried out using Statistical 
Package for Social Sciences® (SPSS) software version 13 
for Windows® (Apache Software Foundation, USA). The 
values of active DHFR, IRE, TLC and number of days for 
resolution of neutropenia were expressed as mean±SD. 
Paired sample t-test and analysis of variance (ANOVA) 
followed by Tukey’s HSD test were used to compare the 
mean values. Variables were considered statistically 
significant at a p-value<0.05. 
 
RESULTS 
 
Significantly increased concentrations of active DHFR 
and IRE as well as TLC were observed when standard 
doses of GM-CSF and G-CSF were used (p<0.05; table 2). 
However, at low dose (100 µg/m2) of GM-CSF, the 
increases in IRE concentration and TLC were found to be 
significant (p<0.05), whereas increase in concentration of 
active DHFR did not reach statistical significance 
probably due to small number of samples in this category 
(table 2). In patients, who received low dose of G-CSF, 
significantly increased TLC and concentrations of both 
active DHFR and IRE were observed (p<0.05). There was 
no significant difference in the number of days for 
resolution of neutropenia at the two dose levels.  
Table 1: Characteristics of neutropenic cancer patients treated with conventional and low doses of GM-CSF and G-
CSF 
 
GM-CSF G-CSF Patient characteristics 250 µg/m2 100 µg/m2 5 µg/kg 2.5 µg/kg 
Age  (Mean±SD years) 34.28±10.14 25.75±2.63 34.78±16.3 39.5±21.6 
Gender (Male: Female) 6:1 3:1 7:7 10.2 
Diagnosis     
‐  Acute myelogenous leukemia 2 1 7 - 
‐  Acute lymphocytic leukemia 3 2 2 3 
‐  Non-Hodgkin’s lymphoma 1 - - 3 
‐  Solid tumors 1 1 5 6 
Total 7 4 14 12 
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In order to clarify whether the increase in cytoplasmic 
active DHFR and IRE could be due to direct stimulation 
of peripheral blood leukocytes by these cytokines, GM-
CSF at two doses was used to stimulate these cells in 
culture for 16 hours. There was no significant increase 
either in TLC, or in concentrations of active DHFR and 
IRE (table 3), indicating that the underlying mechanism 
of the observed increases in vivo is not because of direct 
stimulation by GM-CSF. 
 
DISCUSSION 
 
In a resource-constrained developing country such as 
Pakistan, high cost of medical treatment in cancer patients 
often becomes a limiting factor. Therefore, provision of 
economical medical care remains a challenge in several 
countries. Administration of CSFs has been found to 
reduce hospitalization time and neutrophil recovery 
period in neutropenic cancer patients (Clark et al., 2005). 
Even low doses have been found to be quite effective in 
this regard. For example, in a study in Japan, low doses of 
G-CSF (50 µg/kg to 100 µg/kg) were found to be safe, 
effective and pharmaco-economically beneficial in 
neutropenic patients with non-Hodgkins lymphoma 
(Hashino et al., 2008). A study carried out at the Aga 
Khan University Hospital, Karachi also indicated the 
effectiveness of lower than standard doses of CSFs in the 
treatment of patients with chemotherapy-induced 
neutropenia (Burney et al., 2003). In another study, 
accelerated hematopoietic recovery was seen after 
peripheral blood progenitor cell transplantation by using 
50 µg/m2 of G-CSF (Shimakzaki et al., 1994). In all those 
reports, the mechanism of increased proliferation of white 
blood cells remained undefined. In a previous 
communication, we have shown an association between 
increased TLC and increase in multiple forms of DHFR 
(Iqbal et al., 2001). The results of the present study 
further lend support to these observations and that even 
low doses of CSF have been found to increase both the 
active DHFR and IRE along with increased TLC. 
 
This increase in multiple forms of DHFR could be 
because of induction of these forms as a result of 
stimulation of myeloid precursor cells by CSF or through 
increased stability of the transcripts (Leys et al., 1984). 
Our results pertaining to in vitro culture of peripheral 
blood leukocytes with GM-CSF are suggestive that 
induction of these forms of DHFR in vivo, perhaps, 
involves a more sophisticated mechanism. 
 
One of the limitations of this study is that we monitored 
DHFR in total white blood cells rather than in the 
neutrophils. It is mainly the neutrophil count which 
increases upon administration of CSF. Hence, it would not 
be unreasonable to assume that the observed increase in 
concentrations of active DHFR and IRE in white blood 
cells reflects the increase of these forms of enzyme 
primarily in neutrophils. Like other cytokines, G-CSF is 
Table 2:  Effect of low and full doses of colony-stimulating factors (CSFs) on total leukocyte count, concentrations of 
active DHFR and immunoreactive nonfunctional DHFR (IRE) in leukocyte cytoplasm samples of neutropenic cancer 
patients before and after stimulation with CSFs. 
 
Mean±SD 
Active DHFR 
(ng/mg protein) 
Immunoreactive 
DHFR  
(ng/mg protein) 
Total leukocyte 
count (109/l) CSF Dose No. of Patients 
Before After 
p-
value* 
Before After 
p-
value* 
Before After 
p-
value* 
No. of 
days for 
recovery 
250 
µg/m2 7 
0.36± 
0.51 
1.28± 
0.82 <0.025 
104± 
51.4 
434±3 
09 <0.01 
0.51± 
0.27 
2.9± 
1.16 .005 
8.5± 
5.4 GM-
CSF 100 
µg/m2 4 
0.17± 
0.04 
0.28± 
0.13 NS 
123± 
150 
805± 
645 0<.05 
0.4± 
0.24 
5.6± 
4.7 <0.05 
5.5± 
1.9 
5 
µg/kg 14 
0.6± 
0.52 
4.33 
±7.25 <0.05 
173 
±98 
927± 
1261 
<0.02
5 
0.8± 
0.56 
4.77± 
2.54 <0.001 
7.86± 
5.7 G-
CSF 2.5 
µg/kg 12 
0.146± 
0.07 
0.813 
±0.6 <0.005 
99± 
178 
752± 
811.5 <0.01 
0.77± 
0.526 
8.71± 
10.1 <0.01 
4.4 
±2 
*The p-values compare the values before and after treatment with CSF. NS= Not significant 
 
Table 3: Effect of GM-CSF on peripheral blood leukocytes in vitro for the induction of multiple forms of DHFR over a 
period of 16 hours at 37°C. 
 
Mean±SD 
Dose (U/ml) Number of samples (n) TLC (109/l) Active DHFR  (ng/mg) IRE (ng/mg) 
0 (Control) 17 6.64±1.35 0.127±0.094 335±167 
0.5 8 6.9±1.58 0.095±0.035 340±127 
80 9 5.8±1.5 0.147±0.093 361±180 
IRE= Immunoreactive-non functional form of DHFR, TLC= Total leukocyte count. 
Note: Comparison of mean values of control, treatment group at a dose of 0.5U/ml and treatment group at a dose of 80 U/ml was 
carried out using one-way ANOVA. 
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known to induce intracellular protein tyrosine 
phosphorylation and activate various signaling cascades 
such as, activation of JAK protein tyrosine kinases and 
signal transducers and activators of transcription (STAT) 
proteins and ras-MAP kinase leading to enhanced 
transcription of genes (Tidow and Welte, 1997). Whether 
this cascade leads to DHFR gene transcription remains to 
be clarified. Therefore, further studies are required to 
unravel the molecular mechanism by which CSFs bring 
about proliferation of neutrophils in neutropenic patients. 
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